{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:06:05Z","timestamp":1772769965497,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T00:00:00Z","timestamp":1669507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T00:00:00Z","timestamp":1669507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009634","name":"Susan G. Komen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["K01HS023680"],"award-info":[{"award-number":["K01HS023680"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s10549-022-06810-1","type":"journal-article","created":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T11:30:13Z","timestamp":1669548613000},"page":"547-558","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer"],"prefix":"10.1007","volume":"197","clinical-trial-number":[{"clinical-trial-number":"nct01468246","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0074-6385","authenticated-orcid":false,"given":"Shoshana M.","family":"Rosenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shari","family":"Gelber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn J.","family":"Ruddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Poorvu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tal","family":"Sella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rulla M.","family":"Tamimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Wassermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia","family":"Schapira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia F.","family":"Borges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Come","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Peppercorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen R.","family":"Sepucha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann H.","family":"Partridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,27]]},"reference":[{"issue":"1","key":"6810_CR1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s10549-016-3983-9","volume":"160","author":"H Fredholm","year":"2016","unstructured":"Fredholm H, Magnusson K, Lindstrom LS, Garmo H, Falt SE, Lindman H, Bergh J, Holmberg L, Ponten F, Frisell J, Fredriksson I (2016) Long-term outcome in young women with breast cancer: a population-based study. Breast Cancer Res Treat 160(1):131\u2013143. https:\/\/doi.org\/10.1007\/s10549-016-3983-9","journal-title":"Breast Cancer Res Treat"},{"issue":"27","key":"6810_CR2","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1200\/JCO.2015.65.8013","volume":"34","author":"AH Partridge","year":"2016","unstructured":"Partridge AH, Hughes ME, Warner ET, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Tamimi RM (2016) Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol 34(27):3308\u20133314. https:\/\/doi.org\/10.1200\/JCO.2015.65.8013","journal-title":"J Clin Oncol"},{"issue":"10001","key":"6810_CR3","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"Early Breast Cancer Trialists' Collaborative G","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative G (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386(10001):1341\u20131352. https:\/\/doi.org\/10.1016\/S0140-6736(15)61074-1","journal-title":"Lancet"},{"issue":"9793","key":"6810_CR4","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"C Davies","year":"2011","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative G, Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(11)60993-8","journal-title":"Lancet"},{"issue":"2","key":"6810_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10549-012-2114-5","volume":"134","author":"CC Murphy","year":"2012","unstructured":"Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459\u2013478. https:\/\/doi.org\/10.1007\/s10549-012-2114-5","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"6810_CR6","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1200\/JCO.2003.07.071","volume":"21","author":"AH Partridge","year":"2003","unstructured":"Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21(4):602\u2013606. https:\/\/doi.org\/10.1200\/JCO.2003.07.071","journal-title":"J Clin Oncol"},{"issue":"27","key":"6810_CR7","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1200\/JCO.2009.25.9655","volume":"28","author":"DL Hershman","year":"2010","unstructured":"Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Gomez SL, Miles S, Neugut AI (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28(27):4120\u20134128. https:\/\/doi.org\/10.1200\/JCO.2009.25.9655","journal-title":"J Clin Oncol"},{"key":"6810_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv202","author":"NC Llarena","year":"2015","unstructured":"Llarena NC, Estevez SL, Tucker SL, Jeruss JS (2015) Impact of fertility concerns on tamoxifen initiation and persistence. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djv202","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"6810_CR9","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1158\/1055-9965.EPI-09-1120","volume":"19","author":"JM Gierisch","year":"2010","unstructured":"Gierisch JM, Earp JA, Brewer NT, Rimer BK (2010) Longitudinal predictors of nonadherence to maintenance of mammography. Cancer Epidemiol Biomarkers Prev 19(4):1103\u20131111. https:\/\/doi.org\/10.1158\/1055-9965.EPI-09-1120","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"6810_CR10","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1001\/jama.1992.03480040068032","volume":"267","author":"RB Williams","year":"1992","unstructured":"Williams RB, Barefoot JC, Califf RM, Haney TL, Saunders WB, Pryor DB, Hlatky MA, Siegler IC, Mark DB (1992) Prognostic importance of social and economic resources among medically treated patients with angiographically documented coronary artery disease. JAMA 267(4):520\u20134","journal-title":"JAMA"},{"issue":"20","key":"6810_CR11","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.1200\/JCO.2004.01.159","volume":"22","author":"AH Partridge","year":"2004","unstructured":"Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, Rosenberg R, Przypyszny M, Rein A, Winer EP (2004) Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 22(20):4174\u20134183. https:\/\/doi.org\/10.1200\/JCO.2004.01.159","journal-title":"J Clin Oncol"},{"issue":"6","key":"6810_CR12","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/jnci\/dji069","volume":"97","author":"AL Stanton","year":"2005","unstructured":"Stanton AL, Bernaards CA, Ganz PA (2005) The BCPT symptom scales: a measure of physical symptoms for women diagnosed with or at risk for breast cancer. J Natl Cancer Inst 97(6):448\u2013456. https:\/\/doi.org\/10.1093\/jnci\/dji069","journal-title":"J Natl Cancer Inst"},{"key":"6810_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1472-6947-14-73","volume":"14","author":"CN Lee","year":"2014","unstructured":"Lee CN, Wetschler MH, Chang Y, Belkora JK, Moy B, Partridge A, Sepucha KR (2014) Measuring decision quality: psychometric evaluation of a new instrument for breast cancer chemotherapy. BMC Med Inform Decis Mak 14:73. https:\/\/doi.org\/10.1186\/1472-6947-14-73","journal-title":"BMC Med Inform Decis Mak"},{"issue":"18","key":"6810_CR14","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1001\/jama.1997.03540420081039","volume":"277","author":"LF Degner","year":"1997","unstructured":"Degner LF, Kristjanson LJ, Bowman D, Sloan JA, Carriere KC, O\u2019Neil J, Bilodeau B, Watson P, Mueller B (1997) Information needs and decisional preferences in women with breast cancer. JAMA 277(18):1485\u20131492","journal-title":"JAMA"},{"issue":"3","key":"6810_CR15","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10549-017-4561-5","volume":"167","author":"LK Lambert","year":"2018","unstructured":"Lambert LK, Balneaves LG, Howard AF, Gotay CC (2018) Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review. Breast Cancer Res Treat 167(3):615\u2013633. https:\/\/doi.org\/10.1007\/s10549-017-4561-5","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"6810_CR16","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10549-011-1762-1","volume":"131","author":"JC Livaudais","year":"2012","unstructured":"Livaudais JC, Hershman DL, Habel L, Kushi L, Gomez SL, Li CI, Neugut AI, Fehrenbacher L, Thompson B, Coronado GD (2012) Racial\/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer. Breast Cancer Res Treat 131(2):607\u2013617. https:\/\/doi.org\/10.1007\/s10549-011-1762-1","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"6810_CR17","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s10549-013-2499-9","volume":"138","author":"CR Friese","year":"2013","unstructured":"Friese CR, Pini TM, Li Y, Abrahamse PH, Graff JJ, Hamilton AS, Jagsi R, Janz NK, Hawley ST, Katz SJ, Griggs JJ (2013) Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. Breast Cancer Res Treat 138(3):931\u2013939. https:\/\/doi.org\/10.1007\/s10549-013-2499-9","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"6810_CR18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10549-012-2066-9","volume":"134","author":"AI Neugut","year":"2012","unstructured":"Neugut AI, Hillyer GC, Kushi LH, Lamerato L, Leoce N, Nathanson SD, Ambrosone CB, Bovbjerg DH, Mandelblatt JS, Magai C, Tsai WY, Jacobson JS, Hershman DL (2012) Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: the Breast Cancer Quality of Care Study (BQUAL). Breast Cancer Res Treat 134(1):419\u2013428. https:\/\/doi.org\/10.1007\/s10549-012-2066-9","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"6810_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.clbc.2017.12.002","volume":"18","author":"VB Sheppard","year":"2018","unstructured":"Sheppard VB, de Mendoza AH, He J, Jennings Y, Edmonds MC, Oppong BA, Tadesse MG (2018) Initiation of adjuvant endocrine therapy in black and white women with breast cancer. Clin Breast Cancer 18(5):337-346.e1. https:\/\/doi.org\/10.1016\/j.clbc.2017.12.002","journal-title":"Clin Breast Cancer"},{"issue":"11","key":"6810_CR20","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/onco.13964","volume":"26","author":"KE Reeder-Hayes","year":"2021","unstructured":"Reeder-Hayes KE, Troester MA, Wheeler SB (2021) Adherence to endocrine therapy and racial outcome disparities in breast cancer. Oncologist 26(11):910\u2013915. https:\/\/doi.org\/10.1002\/onco.13964","journal-title":"Oncologist"},{"issue":"1","key":"6810_CR21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1186\/s12885-021-08149-0","volume":"21","author":"KY Eom","year":"2021","unstructured":"Eom KY, van Londen GJ, Li J, Dahman B, Bradley C, Sabik LM (2021) Changes in initiation of adjuvant endocrine therapy for breast cancer after state health reform. BMC Cancer. 21(1):487. https:\/\/doi.org\/10.1186\/s12885-021-08149-0","journal-title":"BMC Cancer."},{"key":"6810_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010107","author":"KI Toivonen","year":"2020","unstructured":"Toivonen KI, Williamson TM, Carlson LE, Walker LM, Campbell TS (2020) Potentially modifiable factors associated with adherence to adjuvant endocrine therapy among breast cancer survivors: a systematic review. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13010107","journal-title":"Cancers (Basel)"},{"issue":"24","key":"6810_CR23","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1200\/JCO.19.01758","volume":"38","author":"B Pistilli","year":"2020","unstructured":"Pistilli B, Paci A, Ferreira AR, Di Meglio A, Poinsignon V, Bardet A, Menvielle G, Dumas A, Pinto S, Dauchy S, Fasse L, Cottu PH, Lerebours F, Coutant C, Lesur A, Tredan O, Soulie P, Vanlemmens L, Jouannaud C, Levy C, Everhard S, Arveux P, Martin AL, Dima A, Lin NU, Partridge AH, Delaloge S, Michiels S, Andre F, Vaz-Luis I (2020) Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk. J Clin Oncol 38(24):2762\u20132772. https:\/\/doi.org\/10.1200\/JCO.19.01758","journal-title":"J Clin Oncol"},{"issue":"6","key":"6810_CR24","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s12529-020-09908-2","volume":"27","author":"JM Jacobs","year":"2020","unstructured":"Jacobs JM, Walsh EA, Park ER, Berger J, Peppercorn J, Partridge A, Horick N, Safren SA, Temel JS, Greer JA (2020) The patient\u2019s voice: adherence, symptoms, and distress related to adjuvant endocrine therapy after breast cancer. Int J Behav Med 27(6):687\u2013697. https:\/\/doi.org\/10.1007\/s12529-020-09908-2","journal-title":"Int J Behav Med"},{"issue":"7","key":"6810_CR25","doi-asserted-by":"publisher","first-page":"e303","DOI":"10.1016\/S1470-2045(20)30666-5","volume":"22","author":"MA Franzoi","year":"2021","unstructured":"Franzoi MA, Agostinetto E, Perachino M, Del Mastro L, de Azambuja E, Vaz-Luis I, Partridge AH, Lambertini M (2021) Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol 22(7):e303\u2013e313. https:\/\/doi.org\/10.1016\/S1470-2045(20)30666-5","journal-title":"Lancet Oncol"},{"issue":"5","key":"6810_CR26","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1093\/jnci\/djy136","volume":"111","author":"SB Wheeler","year":"2019","unstructured":"Wheeler SB, Spencer J, Pinheiro LC, Murphy CC, Earp JA, Carey L, Olshan A, Tse CK, Bell ME, Weinberger M, Reeder-Hayes KE (2019) Endocrine therapy nonadherence and discontinuation in black and white women. J Natl Cancer Inst 111(5):498\u2013508. https:\/\/doi.org\/10.1093\/jnci\/djy136","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"6810_CR27","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10549-010-1132-4","volume":"126","author":"DL Hershman","year":"2011","unstructured":"Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529\u2013537. https:\/\/doi.org\/10.1007\/s10549-010-1132-4","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"6810_CR28","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1038\/sj.bjc.6604758","volume":"99","author":"C McCowan","year":"2008","unstructured":"McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, Fahey TP (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99(11):1763\u20131768. https:\/\/doi.org\/10.1038\/sj.bjc.6604758","journal-title":"Br J Cancer"},{"issue":"5","key":"6810_CR29","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1158\/1078-0432.CCR-20-3974","volume":"27","author":"LJ Collin","year":"2021","unstructured":"Collin LJ, Cronin-Fenton DP, Ahern TP, Goodman M, McCullough LE, Waller LA, Kjaersgaard A, Damkier P, Christiansen PM, Ejlertsen B, Jensen MB, Sorensen HT, Lash TL (2021) Early discontinuation of endocrine therapy and recurrence of breast cancer among premenopausal women. Clin Cancer Res 27(5):1421\u20131428. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3974","journal-title":"Clin Cancer Res"},{"key":"6810_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx041","author":"W He","year":"2017","unstructured":"He W, Smedby KE, Fang F, Olsson H, Margolin S, Hall P, Czene K (2017) Treatment restarting after discontinuation of adjuvant hormone therapy in breast cancer patients. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djx041","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 3","key":"6810_CR31","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.2105\/AJPH.2014.302490","volume":"105","author":"MC Roberts","year":"2015","unstructured":"Roberts MC, Wheeler SB, Reeder-Hayes K (2015) Racial\/ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review. Am J Public Health 105(Suppl 3):e4\u2013e15. https:\/\/doi.org\/10.2105\/AJPH.2014.302490","journal-title":"Am J Public Health"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06810-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-022-06810-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06810-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T05:30:54Z","timestamp":1674797454000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-022-06810-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,27]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["6810"],"URL":"https:\/\/doi.org\/10.1007\/s10549-022-06810-1","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,27]]},"assertion":[{"value":"11 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Rosenberg reports grant funding from Pfizer\/Conquer Cancer. Dr. Borges reports institutional research funding from SeaGen, AstraZeneca, Olema, and Oncosec; consulting fees from SeaGen and AstraZeneca; and stock ownership in PerlaTx. Dr. Peppercorn reports employment at GSK (spouse) and consulting for Abbott Labs (self). Dr. Partridge reports royalties from UpToDate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the IRB. The study was approved by the IRBs of Dana-Farber Harvard Cancer Center and other participating sites (Beth Israel Deaconess Medical Center, Brigham and Women\u2019s Hospital, Brigham and Women\u2019s Faulkner Hospital, Cape Cod Hospital, Lowell General Hospital, Massachusetts General Hospital, Mayo Clinic, Newton-Wellesley Hospital, North Shore Cancer Center Salem, South Shore Hospital, Sunnybrook Health Sciences Center, and University of Colorado).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individuals included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}